Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
absence, ActoBio, andC, appeal, blind, breast, chemoradiation, concurrently, customary, cytotoxic, diarrhea, divisible, double, EE, effector, etiology, flexibility, forClostridium, fractional, Fundamental, hundred, IP, ix, junior, library, lung, millionunsecured, necessarily, nominee, OG, opposed, opted, par, PCAOB, PIK, placebo, postage, proportionate, proportionately, ran, rank, Redeemable, redeemed, refining, remeasured, remeasurement, respond, round, SAB, secondary, SeriesB, SeriesC, Shareholdersof, Simultaneously, statementswe, STOCKHOLDER, Summer, TCJA, thereon, truncated, unadjusted, uncommon
Filing tables
Filing exhibits
OGEN similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the inclusion in this Annual Report (Form10-K) of Oragenics, Inc. of our report dated February 16, 2018, with respect to the 2017 and 2016 financial statements of Oragenics, Inc. We consent to the incorporation of our report by reference in the following Registration Statements:
(i) | FormS-8 Registration Statements (Nos. (Nos.333-110646,333-150716,333-163083,333-177091 and333-184588) of Oragenics, Inc. pertaining to the Oragenics, Inc. 2012 Equity Incentive Plan; and |
(ii) | Registration Statements (FormS-1No. 333-183685) and related Prospectus of Oragenics, Inc. for the registration of 9,437,834 shares of its common stock and (FormS-3No. 333-190609 andNo. 333-213321). |
/s/ Mayer Hoffman McCann P.C.
Clearwater, Florida
February 16, 2018